Teva Pharmaceutical Industries features in the global pharmaceuticals sector, with a mix of branded medicines, generics, and biosimilars shaping attention around its share quote Recent market action ...
Litigators of the Week: A Defense Win for Teva in the First Paragard IUD Bellwether Goldman Ismail’s Shayna Cook and Rami Fakhouri secured a full defense verdict from federal jurors in Atlanta in the ...
Teva Pharmaceuticals USA Inc. won a jury verdict in its favor at the conclusion of the first bellwether trial over claims the company’s Paragard intrauterine contraceptive device was prone to breaking ...
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and ...
Teva faces over 3,800 lawsuits over Paragard IUD claims Trial was the first bellwether to test the claims Teva sold Paragard to CooperSurgical in 2017 Feb 4 (Reuters) - A jury in Atlanta federal court ...
Ancora Teva, ancora un boicottaggio. Dopo i casi sparsi per l’Italia, anche il comune di Monza mette al bando la vendita dei prodotti farmaceutici dell’azienda israeliana. Un segnale per “non essere ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the cheap hot stocks to invest in right now. On January 30, Barclays analyst Glen Santangelo raised the price target for Teva ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Teva Pharmaceutical Industries (TEVA) has become a focus ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the cheap hot stocks to invest in right now. On January 30, Barclays analyst Glen Santangelo raised the price target for Teva ...
Teva Pharmaceutical Industries Ltd. (TEVA) reported a robust financial performance for the fourth quarter of 2025, significantly surpassing market expectations with an earnings per share (EPS) of ...
Teva Pharmaceutical Industries (TEVA) shares snapped six straight sessions of gains, as the stock closed 0.4% lower at $33.07 on Thursday. The generic drugmaker gained about 6% in the preceding six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results